Cerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriers

AIDS

Volumn 26, Issue 18, 2012, Pages 2327-2335

  Soontornniyomkij, Virawudh ^a,b   Moore, David J ^a,b   Gouaux, Ben ^a,b   Soontornniyomkij, Benchawanna ^b   Tatro, Erick T ^a,b   Umlauf, Anya ^a   Masliah, Eliezer ^a,c,d   Levine, Andrew J ^e   Singer, Elyse J ^e   Vinters, Harry V ^e   Gelman, Benjamin B ^f   Morgello, Susan ^g   Cherner, Mariana ^a,b   Grant, Igor ^a,b   Achim, Cristian L ^a,b,c  

^a HIV Neurobehavioral Research Program   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

apolipoprotein E; b amyloid; HIV dementia; neurofibrillary pathology; phospho Tau

Indexed keywords

AMYLOID BETA PROTEIN; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN E4; GENOMIC DNA; TAU PROTEIN;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN; COGNITIVE DEFECT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEUROFIBRILLARY TANGLE; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION;

ADULT; AGED; AIDS DEMENTIA COMPLEX; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; BRAIN; CEREBRAL AMYLOID ANGIOPATHY; EXECUTIVE FUNCTION; FEMALE; GENOTYPE; HIV INFECTIONS; HUMANS; IMMUNOHISTOCHEMISTRY; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84870242810     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835a117c     Document Type: Article

References (55)

1. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011;17:3-16.
2. Nath A, Schiess N, Venkatesan A, Rumbaugh J, Sacktor N, McArthur J. Evolution of HIV dementia with HIV infection. Int Rev Psychiatry 2008;20:25-31. (Pubitemid 351196197)
3. Jayadev S, Garden GA. Host and viral factors influencing the pathogenesis of HIV-associated neurocognitive disorders. J Neuroimmune Pharmacol 2009;4:175-189.
4. Rempel HC, Pulliam L. HIV-1 Tat inhibits neprilysin and elevates amyloid beta. AIDS 2005;19:127-135. (Pubitemid 40409531)
5. Esiri MM, Biddolph SC, Morris CS. Prevalence of Alzheimer plaques in AIDS. J Neurol Neurosurg Psychiatry 1998;65:29-33. (Pubitemid 28302353)
6. Izycka-Swieszewska E, Zółtowska A, Rzepko R, Gross M, Borowska-Lehman J. Vasculopathy and amyloid beta reactivity in brains of patients with acquired immune deficiency (AIDS). Folia Neuropathol 2000;38:175-182. (Pubitemid 36050179)
7. Achim CL, Adame A, Dumaop W, Everall IP, Masliah E. Increased accumulation of intraneuronal amyloid beta in HIV-infected patients. J Neuroimmune Pharmacol 2009;4:190-199.
8. Green DA, Masliah E, Vinters HV, Beizai P, Moore DJ, Achim CL. Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS 2005;19:407-411. (Pubitemid 40446187)
9. Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE. Accelerated Tau deposition in the brains of individuals infected with human immunodeficiency virus-1 before and after the advent of highly active antiretroviral therapy. Acta Neuropathol 2006;111:529-538. (Pubitemid 43778957)
10. Clifford DB, Fagan AM, Holtzman DM, Morris JC, Teshome M, Shah AR, et al. CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. Neurology 2009;73:1982-1987.
11. Brew BJ, Pemberton L, Blennow K, Wallin A, Hagberg L. CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology 2005;65:1490-1492. (Pubitemid 41552790)
12. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006;59:512-519. (Pubitemid 43358072)
13. Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, et al. Cerebrospinal fluid tau and ptau (181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 2009;1:371-380.
14. Gisslén M, Krut J, Andreasson U, Blennow K, Cinque P, Brew BJ, et al. Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol 2009;9:63.
15. Polvikoski T, Sulkava R, Haltia M, Kainulainen K, Vuorio A, Verkkoniemi A, et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med 1995;333:1242-1247.
16. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010;67:122-131.
17. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-923. (Pubitemid 23275809)
18. Mahley RW, Rall SCJ. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000;1:507-537.
19. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009;63:287-303.
20. Castellano JM, Kim J, Stewart FR, Jiang H, De Mattos RB, Patterson BW, et al. Human apoE isoforms differentially regulate brain amyloid-b peptide clearance. Sci Transl Med 2011;3:89ra57.
21. Corder EH, Paganelli R, Giunta S, Franceschi C. Differential course of HIV-1 infection and APOE polymorphism. Proc Natl Acad Sci U S A 2008;105:E87.
22. Burt TD, Agan BK, Marconi VC, He W, Kulkarni H, Mold JE, et al. Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression. Proc Natl Acad Sci U S A 2008;105:8718-8723. (Pubitemid 351987746)
23. Diaz-Arrastia R, Gong Y, Kelly CJ, Gelman BB. Host genetic polymorphisms in human immunodeficiency virus-related neurologic disease. J Neurovirol 2004;10(Suppl 1):67-73. (Pubitemid 38325096)
24. Dunlop O, Goplen AK, Liestøl K, Myrvang B, Rootwelt H, Christophersen B, et al. HIV dementia and apolipoprotein E. Acta Neurol Scand 1997;95:315-318. (Pubitemid 27214484)
25. Pemberton LA, Stone E, Price P, van Bockxmeer F, Brew BJ. The relationship between ApoE, TNFA, IL1a, IL1b and IL12b genes and HIV-1-associated dementia. HIV Med 2008;9:677-680.
26. Pomara N, Belzer KD, Silva R, Cooper TB, Sidtis JJ. The apolipoprotein E epsilon4 allele and memory performance in HIV-1 seropositive subjects: differences at baseline but not after acute oral lorazepam challenge. Psychopharmacology (Berl) 2008;201:125-135.
27. Levine AJ, Hinkin CH, Ando K, Santangelo G, Martinez M, Valdes-Sueiras M, et al. An exploratory study of long-term neurocognitive outcomes following recovery from opportunistic brain infections in HIVRadults. J Clin Exp Neuropsychol 2008;30:836-843.
28. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007;69:1789-1799. (Pubitemid 350059308)
29. Hasin DS, Trautman KD, Miele GM, Samet S, Smith M, Endicott J. Psychiatric Research Interview for Substance and Mental Disorders (PRISM): reliability for substance abusers. Am J Psychiatry 1996;153:1195-1201. (Pubitemid 26299841)
30. Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, et al. The Composite International Diagnostic Interview. An epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry 1988;45:1069-1077. (Pubitemid 19005460)
31. Soontornniyomkij V, Everall IP, Moore DJ, Gouaux B, Tatro ET, Gospodarev V, et al. Increased cortical expression of FK506 binding protein-51 in HIV-associated neurocognitive disorders. J Neurovirol 2012;18:313-322.
32. Duyckaerts C, Delatour B, Potier MC. Classification and basic pathology of Alzheimer disease. Acta Neuropathol 2009;118:5-36.
33. Vonsattel JP, Myers RH, Hedley-Whyte ET, Ropper AH, Bird ED, Richardson EP. Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann Neurol 1991;30:637-649.
34. Alafuzoff I, Arzberger T, Al-Sarraj S, Bodi I, Bogdanovic N, Braak H, et al. Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. Brain Pathol 2008;18:484-496.
35. Thal DR, Rüb U, Orantes M, Braak H. Phases of A betadeposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791-1800. (Pubitemid 34663580)
36. Davis DG, Schmitt FA, Wekstein DR, Markesbery WR. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 1999;58:376-388. (Pubitemid 29187900)
37. Metsaars WP, Hauw JJ, van Welsem ME, Duyckaerts C. A grading system of Alzheimer disease lesions in neocortical areas. Neurobiol Aging 2003;24:563-572. (Pubitemid 36513704)
38. Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 2011;70:960-969.
39. Kantarci K, Lowe V, Przybelski SA, Weigand SD, Senjem ML, Ivnik RJ, et al. APOE modifies the association between Ab load and cognition in cognitively normal older adults. Neurology 2012;78:232-240.
40. Ances BM, Benzinger TL, Christensen JJ, Thomas J, Venkat R, Teshome M, et al. 11C-PiB imaging of human immunodeficiency virus-associated neurocognitive disorder. Arch Neurol 2012;69:72-77.
41. Klunk WE. Amyloid imaging as a biomarker for cerebral b-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging 2011;32(Suppl 1):S20-36.
42. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003;46:2740-2754. (Pubitemid 36702542)
43. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Postmortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008;131:1630-1645. (Pubitemid 351806448)
44. Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L, et al. PIB is a nonspecific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain 2007;130:2607-2615. (Pubitemid 47511709)
45. Yamaguchi H, Nakazato Y, Hirai S, Shoji M, Harigaya Y. Electron micrograph of diffuse plaques. Initial stage of senile plaque formation in the Alzheimer brain. Am J Pathol 1989;135:593-597. (Pubitemid 19268015)
46. Zlokovic BV, Deane R, Sallstrom J, Chow N, Miano JM. Neurovascular pathways and Alzheimer amyloid beta-peptide. Brain Pathol 2005;15:78-83. (Pubitemid 40224070)
47. Hawkes CA, McLaurin J. Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Proc Natl Acad Sci U S A 2009;106:1261-1266.
48. Abbott NJ. Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochem Int 2004;45:545-552. (Pubitemid 38739482)
49. Bell RD, Zlokovic BV. Neurovascular mechanisms and bloodbrain barrier disorder in Alzheimer's disease. Acta Neuropathol 2009;118:103-113.
50. Carare RO, Bernardes-Silva M, Newman TA, Page AM, Nicoll JA, Perry VH, et al. Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol Appl Neurobiol 2008;34:131-144. (Pubitemid 351327967)
51. Scott JC, Woods SP, Matt GE, Meyer RA, Heaton RK, Atkinson JH, et al. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev 2007;17:275-297. (Pubitemid 47498174)
52. Iversen LL, Iversen SD, Bloom FE, Roth RH. Psychostimulants. Introduction to neuropsychopharmacology. Oxford: Oxford University Press; 2009. pp. 447-472.
53. Cirrito JR, Disabato BM, Restivo JL, Verges DK, Goebel WD, Sathyan A, et al. Serotonin signaling is associated with lower amyloid-b levels and plaques in transgenic mice and humans. Proc Natl Acad Sci U S A 2011;108:14968-14973.
54. Green AJ, Giovannoni G, Hall-Craggs MA, Thompson EJ, Miller RF. Cerebrospinal fluid tau concentrations in HIV infected patients with suspected neurological disease. Sex Transm Infect 2000;76:443-446. (Pubitemid 32055921)
55. Ellis RJ, Seubert P, Motter R, Galasko D, Deutsch R, Heaton RK, et al. Cerebrospinal fluid tau protein is not elevated in HIV-associated neurologic disease in humans. HIV Neurobehavioral Research Center Group (HNRC). Neurosci Lett 1998;254:1-4. (Pubitemid 28430610)